Theriva^™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase IIb Trial of VCN-01 with Gemcitabine/Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva ™ Biologics, Inc. announced that it has achieved their target patient enrollment in the VIRAGE Phase IIb clinical trial evaluating their lead product candidate VCN-01 plus standard-of-care chemotherapy as a first line therapy for patients with metastatic PDAC.